Background {#Sec1}
==========

Diabetic nephropathy (DN) is a kidney disease characterized by persistent albuminuria, progressive decline in glomerular filtration rate (GFR) and raised arterial blood pressure \[[@CR1]\]. Diabetic nephropathy is a worldwide public health problem, and it is the leading cause of end-stage renal disease (ESRD) in most parts of the developed world \[[@CR2]\]. It is associated with increased cardiovascular mortality \[[@CR3]\]. Approximately one-third to half of patients with diabetes develops renal manifestations \[[@CR4]\]. In Cameroon, diabetic nephropathy is the second leading cause of end stage renal disease and dialysis \[[@CR5]\].

Microalbuminuria, an early marker of diabetic nephropathy can progress to macroalbuminuria and ESRD \[[@CR6]--[@CR8]\] but early screening, medical treatment and appropriate lifestyle modifications have been shown to halt or reverse the progression from micro- to macroalbuminuria \[[@CR8]\]. Hence, it is recommended that microalbuminuria be screened in all diabetic patients annually \[[@CR9]\]. Studies in Africa have reported prevalence of microalbuminuria in diabetic patients ranging from 10 to 44% \[[@CR10], [@CR11]\] and up to 61% in the United Arab Emirates \[[@CR12]\]. In Cameroon, Sobngwi et al. in 1999 reported microalbuminuria prevalence of 53.1% amongst diabetic patients in a tertiary care hospital, which was strongly associated with diabetic retinopathy \[[@CR13]\]. Despite these data, access to routine microalbuminuria testing in sub-Saharan Africa (SSA) is hindered by costs, thus, most patients with diabetes perform dipstick proteinuria only.

The aim of this study was to determine the prevalence of microalbuminuria and to identify associated factors, in patients with type 2 diabetes who screened negative for dipstick proteinuria, in the two regional hospitals of the South West Region of Cameroon.

Methods {#Sec2}
=======

Study design, setting and population {#Sec3}
------------------------------------

This was a hospital-based cross-sectional study conducted at the diabetic clinics of Buea and Limbe regional hospitals. These are the two regional hospitals of the South West Region of Cameroon. Consenting participants coming for routine diabetes follow-up were consecutively recruited. Patients who presented with a febrile illness, overt proteinuria, urinary tract infection, pregnancy, diagnosed or suspected renal, hepatic or other systemic disease were excluded from the study. Those who had done intensive physical activity within the preceding 72 h were ask to come back after 72 h without intensive exercise, for inclusion.

Data collection {#Sec4}
---------------

### Clinical assessment {#Sec5}

A data collection form was used for each patient. The principal investigator collected data on medical and family history; the weight, height and blood pressure were measured using standard methods. The body mass index (BMI) was calculated as weight (kg)/\[height (m)\]^2^ and classified based on WHO classification \[[@CR14]\].

### Laboratory procedures {#Sec6}

#### Urine collection and transportation {#Sec7}

A second morning mid-stream urine sample (10 mL) was collected in a container with no preservatives. Collected urine was put immediately into a cooler containing ice pack, and transported to the laboratory for analysis. Samples not analysed on the day of collection were stored at 2--4 °C.

#### Urine screening {#Sec8}

During analysis, urine samples were first screened for any urinary indicator of urinary tract infection (leukocytes, nitrites), overt proteinuria and glycosuria using ACON^®^ Urinalysis Reagent Strips with 11 parameters. Participants whose samples tested positive for leukocytes, nitrites or glycosuria were treated and urine recollected after 3 weeks, while those with overt proteinuria were excluded. The same urine sample used to assess for proteinuria was used to assess for microalbuminuria. All proteinuric patients tested positive for albuminuria, and they were excluded from the study.

#### Assessment for microalbuminuria {#Sec9}

Two screening methods (qualitative and quantitative analysis) were used to screen for microalbuminuria using the same urine sample. Qualitatively, special microalbumin semi-quantitative urine-testing strips (CYBOW™2MAC) were used to test for microalbuminuria according to manufacturer's instructions \[[@CR15]\].

Quantitatively, microalbuminuria was assessed by determining urine albumin-to-creatinine ratio (UACR) from values obtained from measurements of urine creatinine and urine albumin. Urine creatinine was analysed using the modified kinetic Jaffé method while urine albumin was detected by using acid precipitation reaction between urine albumin and 12% trichloroacetic acid. The turbidity of the precipitate formed was measured spectrophotometrically. UACR was calculated and categorised as microalbuminuria if it was between 30--300 mg/g and normoalbuminuria if it was \<30 mg/g based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) guidelines \[[@CR16]\]. A second urine sample was collected from those who presented with microalbuminuria (UACR between 30 and 300 mg/g).

### Other biochemical assessments and calculations {#Sec10}

Serum total cholesterol, high density lipoprotein-cholesterol (HDLc), triglycerides, serum creatinine, and plasma glucose were measured by spectrophotometry and expressed in mg/dL. Low density lipoprotein-LDL (LDLc) was calculated using the Friedewald equation. Renal function was assessed using the estimated glomerular filtration rate (eGFR) calculated from the modification of diet in renal disease (MDRD) formula \[[@CR17]\].

Sample size estimation {#Sec11}
----------------------

The minimum sample size (n) was calculated using the following formula: $\documentclass[12pt]{minimal}
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                \begin{document}$${\text{n}} = {\text{p q }}\left( {{\text{Z}}_{\alpha / 2} /{\text{E}}} \right)^{ 2}$$\end{document}$ where p was the expected prevalence, assumed to be 10.7% \[[@CR11]\], E represents the maximum error of estimate set at 5% (0.05), for a confidence interval (CI) of 95% and Z~α/2~ is a constant dependent on the CI, 1.96. And q = 1−p (0.873). Computing the foregoing yields a minimum sample size of 147 participants.

Data management and analysis {#Sec12}
----------------------------

Data were analyzed using SPSS (Statistical Package for Social Sciences) Version 17.0 and STATA version 10.1. Results are presented as counts, percentages, means and standard deviations where applicable. Factors associated with microalbuminuria were investigated using linear regressions. A p value \<0.05 was considered statistically significant.

Results {#Sec13}
=======

General characteristics of participants {#Sec14}
---------------------------------------

Of the 162 consenting participants included, 67.3% (109) were females. Participants' age ranged from 24 to 70 years, with mean age of 55.3 ± 10.2 years (Table [1](#Tab1){ref-type="table"}). More than a third of the participants (36%) were in the age group of 50--59 years.Table 1Comparison of characteristics of patients with microalbuminuria and those withoutParameterNormoalbuminuria\
n (%)Microalbuminuria\
n (%)p valueSex0.464 Male, n (%)47 (88.7)6 (11.3) Female, n (%)92 (84.4)17 (15.6)Age (years)55.1 ± 10.556.30 ± 8.30.302Known duration of diabetes (years)6.1 ± 6.46.3 ± 5.20.458BMI (kg/m^2^)29.8 ± 0.527.6 ± 0.80.046\*SBP (mmHg)142.2 ± 21.1151.8 ± 28.40.032\*DBP (mmHg)89.0 ± 19.697.2 ± 18.50.032\*Fasting capillary glucose (mg/dL)151.1 ± 4.3156.0 ± 12.70.676HDLc (mg/dL)76.5 ± 2.776.9 ± 5.40.478LDLc (mg/dL)75.2 ± 40.269.63 ± 39.60.538Triglycerides (mg/dL)123.9 ± 5.9133.8 ± 10.80.257Total cholesterol (mg/dL)173.9 ± 4.2167.54 ± 9.70.569Serum creatinine (mg/dL)0.9 ± 0.031.6 ± 0.1\<0.001\*eGFR (mL/min/1.7 m^2^)101.3 ± 3.946.5 ± 2.3\<0.001\**BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *HDLc* high density lipoprotein cholesterol, *LDLc* low density lipoprotein cholesterol, *SPB* systolic blood pressure\* Statistically significant (p value \<0.05)

Prevalence of microalbuminuria {#Sec15}
------------------------------

Using qualitative special microalbuminuria urine dipsticks, 43 participants \[26.5% (95% CI 19.8--34.0)\] were positive for microalbuminuria, while quantitative analyses showed that 23 participants \[14.2% (95% CI 8.8--19.6%)\] had microalbuminuria (UACR 30--300 mg/g). In 28 participants \[17.3% (95% CI 7.9--26.8%)\], the eGFR was \<60 mL/min/1.73 m^2^.

Associations with microalbuminuria {#Sec16}
----------------------------------

The mean systolic blood pressure (p = 0.032), diastolic blood pressure (p = 0.032) and serum creatinine concentration (p \< 0.001) were higher in people with microalbuminuria as compared to those with normoalbuminuria (Table [1](#Tab1){ref-type="table"}). The mean BMI (p = 0.046) and mean eGFR (p \< 0.001) in the microalbuminuric group were lower when compared with the normoalbuminuric group (Table [1](#Tab1){ref-type="table"}).

In a bivariate linear regression, microalbuminuria was associated with higher systolic blood pressure (p = 0.008), higher diastolic blood pressure (p = 0.015), higher serum creatinine (p \< 0.001) and lower eGFR (p \< 0.001) as shown in Table [2](#Tab2){ref-type="table"}.Table 2Linear regression analysis for associations with microalbuminuriaVariablesSlope coefficient95% CIpSBP0.390.10 to 0.680.008\*DBP0.430.09 to 0.770.015\*Serum creatinine75.7163.17 to 88.25\<0.001\*eGFR−0.33−0.46 to −0.21\<0.001\*\* Statistically significant (p value \<0.05)*DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *SBP* systolic blood pressure

In multivariable linear regression, only eGFR (p = 0.001) and serum creatinine concentration (p = 0.003) were independently associated with increased UACR (Table [3](#Tab3){ref-type="table"}).Tabel 3Multiple regression analysis for associations with microalbuminuriaVariablesSlope coefficient95% CIpSBP0.11−0.15 to 0.360.41DBP0.06−0.24 to −0.360.69eGFR−0.3−0.45 to −0.150.001\*Serum creatinine103.2484.00 to 122.090.003\*\* Statistically significant (p value \<0.05)*DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *SBP* systolic blood pressure

Discussion {#Sec17}
==========

In this study, we found that 14.2% of non-proteinuric type 2 diabetic patients had microalbuminuria, which was associated with elevated blood pressure and declining kidney function. Reported prevalence of microalbuminuria in patients with diabetes varies widely, ranging from 10 to 61% \[[@CR10]--[@CR13], [@CR18], [@CR19]\], and this is probably attributable to differences in screening methods, diagnostic criteria, known duration of diabetes, the degree of control of other cardiovascular risk factors and ethnicity of study populations. The Buea and Limbe regional hospitals of the South west region of Cameroon were selected for this study due to proximity and also because such a study had never been done in these populations. However, an earlier study by Sobngwi et al. \[[@CR13]\] on microalbuminuria in Cameroonians with diabetes included only patients from a tertiary hospital in Yaoundé in the Centre region of Cameroon and the reported prevalence was 53%, this difference in prevalence is partly explained by the high burden of microvascular complications often seen in tertiary care hospital attendees, relative to primary care settings as was the case in our study.

It has been shown that, with the presence of microalbuminuria, glomerular filtration declines by an average of 10--12 mL/min/year, and is accelerated by hypertension, though it is potentially reversible \[[@CR6], [@CR20]\]. Mogensen et al. reported a significant increase in cardiovascular and total mortality in subjects with type 2 diabetes who had microalbuminuria \[[@CR21]\]. Hypertension leads to increased glomerular filtration pressure, thereby promoting abnormal glomerular permeability that enables albumin ultrafiltration \[[@CR21]\]. Similar to most studies \[[@CR10], [@CR11], [@CR22]\], this study confirms that microalbuminuria is associated with elevated systolic and diastolic blood pressures, thus emphasizing the importance of optimal blood pressure control \[[@CR23]\] and underscoring the potential importance of routine MA screening especially in diabetic patients with coincident hypertension.

Smulders et al. reported that diabetic dyslipidemia (high serum triglyceride and low HDL cholesterol levels) is a predictor of rapid progression of microalbuminuria in patients with well-controlled blood pressure. However, like in other studies \[[@CR11], [@CR22], [@CR24]\], we found no significant correlation between microalbuminuria and serum triglycerides and cholesterol levels.

Poor glycemic control favors the progression of diabetes complications \[[@CR25]\]. Although not statistically significant in this study, patients with microalbuminuria had higher fasting blood glucose levels, compared to their normoalbuminuric counterparts. Prospective diabetes trials have proved the importance of optimal glycemic control in preventing the occurrence and progression of diabetic complications including microalbuminuria \[[@CR26]\].

It is evident that microalbuminuria is a significant problem amongst Cameroonian type 2 diabetic patients in a primary care setting and as such routine screening for microalbuminuria which heralds severe renal dysfunction should be instituted universally in Cameroon. This is important because subtle derangements in kidney function (like microalbuminuria) are potentially preventable and/or reversible by judicious use of angiotesin-converting-enzyme inhibitors for optimal blood pressure control in type to diabetic patients \[[@CR27]\].

We acknowledge the following potential limitations: the role angiotensin converting enzyme inhibitor or angiotensin receptor blockers on prevalence of microalbuminuria was not assessed. Also, we could not use HbA1c to evaluated glycemic control because it is not available in these regional hospitals. However, this study to the best of our knowledge is amongst the rare studies in Cameroon that has assessed epidemiology of microalbuminuria in diabetic patients with negative dipstick proteinuria in a primary healthcare setting.

Conclusions {#Sec18}
===========

One in every seven proteinuria-negative type 2 diabetic patients attending the out-patient diabetic clinics in a primary care setting in Cameroon has microalbuminuria. Microalbuminuria is associated with elevated blood pressure and low eGFR. This study emphasises the urgent need to increase the access to microalbuminuria testing so as to allow all diabetic patient with negative dipstick proteinuria to benefit. It also raises the importance of optimal blood pressure control in diabetic patients so as to prevent associated renal and cardiovascular complications.
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